Frova (frovatriptan) is a small molecule pharmaceutical. Frovatriptan was first approved as Frova on 2001-11-08. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1B and 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 1A.
|Drug Class||Antimigraine agents (5-HT1 receptor agonists),sumatriptan derivatives|